Experimental Agents Which Inhibit Hepatocarcinogenesis

Publisher： Karger

E-ISSN： 1423-0232|75|1|17-21

ISSN： 0030-2414

Source： Oncology, Vol.75, Iss.1, 2008-12, pp. : 17-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis‐promoted hepatocarcinogenesis in rats

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 126, Iss. 8, 2010-04 ,pp. : 1788-1796

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prescribing Cyclic Antidepressants for Vitiligo Patients: Which Agents Are Superior, Which Are Not?

By  

Psychotherapy and Psychosomatics, Vol. 72, Iss. 6, 2003-10 ,pp. : 361-362

Karger

Access to resources Recommend Favorite

Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 5-6, 2003-08 ,pp. : 216-217

Karger

Access to resources Recommend Favorite

Molecular Pathology in Early Hepatocarcinogenesis

By  

Oncology, Vol. 78, Iss. 2, 2010-04 ,pp. : 157-160

Karger

Access to resources Recommend Favorite

Molecular Mechanism of Viral Hepatocarcinogenesis

By  

Oncology, Vol. 62, Iss. 1, 2002-01 ,pp. : 29-37

Karger

Access to resources Recommend Favorite